In a report released today, Matt Hewitt from Craig-Hallum maintained a Buy rating on Streamline Health Solutions (STRM – Research Report). The company’s shares closed last Friday at $0.74.
Hewitt covers the Healthcare sector, focusing on stocks such as Apyx Medical, Repligen, and Omnicell. According to TipRanks, Hewitt has an average return of -3.8% and a 35.65% success rate on recommended stocks.
Streamline Health Solutions has an analyst consensus of Moderate Buy, with a price target consensus of $2.00, a 170.27% upside from current levels. In a report released today, Lake Street also assigned a Buy rating to the stock with a $2.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $2.35 and a one-year low of $0.68. Currently, Streamline Health Solutions has an average volume of 120.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Streamline Health Solutions (STRM) Company Description:
Streamline Health Solutions, Inc. engages in the provision of transformational data-driven solutions for healthcare organizations. It solutions includes health information management (HIM), Coding and CDI; evaluator coding analysis platform; financial management; and patient care. It also offers audit, custom integration, training, electronic image conversion, and database monitoring services. The company was founded by J. Brian Patsy in October 1989 and is headquartered in Atlanta, GA.
Read More on STRM:
- Streamline Health announces new RevID contract with Georgia healthcare provider
- Streamline Health price target lowered to $2 from $3 at Lake Street
- Streamline Health reports Q2 EPS (4c), consensus (5c)
- Streamline Health® Reports Fiscal Second Quarter Financial Results
- STRM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
